Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

Status unconfirmed · Phase 1

Conditions studied: Renal Replacement Therapy, Pharmacokinetics

In brief

This investigation is intended to collect safety information for the technique of mixing cefazolin in the CRRT solution on the CRRT circuit, the patient, in addition to collecting information regarding the ability to obtain therapeutic cefazolin serum concentrations

Key facts

Study ID

NCT03672149

Run by

Drexel University

People needed

20

Starts

2019-07-18

Expected to finish

2022-12-31

Last updated by the study team

2020-10-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients eligible to participate in the study must have a need for continuous renal replacement therapy (CRRT) of any modality:
• CVVH-continuous veno-venous hemofiltration
• CVVHD-continuous veno-venous hemodialysis
• CVVHDF-continuous veno-venous hemodiafiltration

You may not qualify if…

• Patients will be considered ineligible if they meet any of the following criteria:
• History of any moderate or severe hypersensitivity or allergic reaction to cefazolin (a history of mild rash followed by uneventful re-exposure and/or red man syndrome is not a contraindication)
• Any rapidly-progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator)
• Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data
• Females that are pregnant or breastfeeding

Where it is running

• St. Christopher's Hospital for Children — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.